MARCKS and hereditary clear cell renal cell carcinoma: After MARCKS knock-down in renal cell carcinoma cells, the efficacy of the tyrosine kinase inhibitor Regorafenib was enhanced, whereas MARCKS attenuation by MANS led to inactivation of AKT and mTOR.